The Importance of Sphingosine Kinase in Breast Cancer: A Potential for Breast Cancer Management.
breast neoplasms
sphingosine kinase
sphingosine-1-phosphate
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
18 Feb 2021
18 Feb 2021
Historique:
entrez:
24
3
2021
pubmed:
25
3
2021
medline:
25
3
2021
Statut:
epublish
Résumé
Breast cancer management includes a combination of surgery, radiation therapy, and chemotherapy. While this management has proven effective, it is not perfect. To expand the umbrella of management to resistant breast cancer tumors, researchers have explored the idea of sphingosine kinase (SphK) and sphingosine-1-phosphate (S1P) as a potential target for treatment. In this article, we review the mechanism of the sphingosine kinase/sphingosine-1-phosphate (SphK/S1P) axis along with its effect on the tumor microenvironment (TME) and compounds that have been studied inhibiting the SphK/S1P axis. We searched for relevant articles in the last five years in Medline and PubMed Central. Inclusion criteria, exclusion criteria, and quality checklists were applied to identify the most relevant articles. We compiled the information that has been summarized in the respective tables and figures provided in this review. The metabolism of sphingolipids was summarized, followed by the SphK/S1P upregulation in breast cancer cells. The variety of effects by upregulation of SphK led to an increase in inflammation, growth, and metastasis in breast cancer tumors. The increase in S1P also impacted the TME, including the cells and surrounding tissue, allowing the breast tumors to thrive. The final point made was a summary of the compounds and drugs that inhibited the SphK/S1P axis. They have proven their effectiveness and show even greater efficacy in combination with docetaxel and doxorubicin in preclinical studies. In conclusion, what is known about the SphK/S1P axis within breast cancer cells is immense but incomplete as we summarize what is known so far. Having a complete picture will allow a faster transition to application in the clinical field but clinical trials have not commenced as of yet.
Identifiants
pubmed: 33758708
doi: 10.7759/cureus.13413
pmc: PMC7978154
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
e13413Informations de copyright
Copyright © 2021, Patel et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Adv Biol Regul. 2020 Jan;75:100670
pubmed: 31708456
Carcinogenesis. 2018 Jan 12;39(1):47-55
pubmed: 28968647
Int J Mol Sci. 2020 Sep 13;21(18):
pubmed: 32933189
Oncotarget. 2018 Jun 29;9(50):29453-29467
pubmed: 30034630
Cell Death Dis. 2019 Feb 27;10(3):200
pubmed: 30814488
Breast Cancer Manag. 2015 Oct;4(5):241-244
pubmed: 27293484
Oncogenesis. 2015 Jun 08;4:e156
pubmed: 26053034
Transl Oncol. 2021 Jan;14(1):100926
pubmed: 33157518
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
Breast Cancer Res Treat. 2018 Nov;172(1):33-43
pubmed: 30043096
Cells. 2020 Jan 06;9(1):
pubmed: 31935914
Pharmacol Ther. 2020 Mar;207:107464
pubmed: 31863815
Mol Cancer Res. 2018 Jun;16(6):1059-1070
pubmed: 29523764
Breast Cancer Res Treat. 2017 Oct;165(3):531-543
pubmed: 28695300
Iran J Pathol. 2017 Summer;12(3):218-224
pubmed: 29531546
J Surg Res. 2017 Nov;219:202-213
pubmed: 29078883
Int J Mol Sci. 2017 Nov 24;18(12):
pubmed: 29186783
Cancers (Basel). 2020 Jul 01;12(7):
pubmed: 32630169
Am J Transl Res. 2017 Dec 15;9(12):5684-5695
pubmed: 29312521
Cancer Res. 2019 Aug 15;79(16):4211-4226
pubmed: 31239273
BMC Cancer. 2020 Aug 15;20(1):766
pubmed: 32799825
Tumour Biol. 2017 Apr;39(4):1010428317699133
pubmed: 28381169
Cells. 2020 Apr 04;9(4):
pubmed: 32260399
Mediators Inflamm. 2017;2017:2076239
pubmed: 28912626
Med Sci Monit. 2018 Apr 01;24:1912-1923
pubmed: 29605826
Adv Biol Regul. 2018 Jan;67:59-65
pubmed: 29055687
Anticancer Res. 2017 Oct;37(10):5469-5475
pubmed: 28982858
BMC Cancer. 2017 Dec 5;17(1):820
pubmed: 29207959
Sci Rep. 2016 Feb 15;6:21564
pubmed: 26877098
Cancer Res. 2018 Apr 1;78(7):1713-1725
pubmed: 29351902
Mediators Inflamm. 2017;2017:4806541
pubmed: 29269995
Oncol Lett. 2017 Jul;14(1):63-72
pubmed: 28693136
Front Pharmacol. 2019 Mar 27;10:303
pubmed: 30971929
Tissue Cell. 2020 Aug;65:101380
pubmed: 32746988
Front Oncol. 2020 Mar 20;10:289
pubmed: 32266132
Front Pharmacol. 2020 Sep 25;11:529962
pubmed: 33101013
PLoS One. 2018 May 2;13(5):e0196854
pubmed: 29718989
Biomed Res Int. 2015;2015:638526
pubmed: 26221601
Oncotarget. 2016 May 17;7(20):29563-76
pubmed: 27129165